Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg.
BACKGROUND
Phase response curves (PRCs) to melatonin exist, but none compare different doses of melatonin using the same protocol.


OBJECTIVE
The aim was to generate a PRC to 0.5 mg of oral melatonin and compare it to our previously published 3.0 mg PRC generated using the same protocol.


METHODS
The study included two 5-d sessions in the laboratory, each preceded by 7-9 d of fixed sleep times. Each session started and ended with a phase assessment to measure the dim light melatonin onset (DLMO). In between were 3 d in an ultradian dim light (<150 lux)/dark cycle (light:dark, 2.5:1.5).


METHODS
Healthy adults (16 men, 18 women) between the ages of 18 and 42 yr participated in the study.


METHODS
During the ultradian days of the laboratory sessions, each participant took one pill per day at the same clock time (0.5 mg melatonin or placebo, double blind, counterbalanced).


METHODS
Phase shifts to melatonin were derived by subtracting the phase shift to placebo. A PRC with time of pill administration relative to baseline DLMO and a PRC relative to midpoint of home sleep were generated.


RESULTS
Maximum advances occurred when 0.5 mg melatonin was taken in the afternoon, 2-4 h before the DLMO, or 9-11 h before sleep midpoint. The time for maximum phase delays was not as distinct, but a fitted curve peaked soon after wake time.


CONCLUSIONS
The optimal administration time for advances and delays is later for the lower dose of melatonin. When each dose of melatonin is given at its optimal time, both yield similarly sized advances and delays.
Burgess
Helen J
HJ
Biological Rhythms Research Laboratory, Department of Behavioral Sciences, Rush University Medical Center, Chicago, IL 60612, USA. Helen_J_Burgess@rush.edu
Revell
Victoria L
VL
Molina
Thomas A
TA
Eastman
Charmane I
CI
D000293:Adolescent; D000328:Adult; D019540:Area Under Curve; D002940:Circadian Rhythm / Q000187:drug effects* / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008550:Melatonin / Q000008:administration & dosage* / Q000502:physiology; D017440:Photoperiod; D012890:Sleep / Q000187:drug effects / Q000502:physiology
D008550:Melatonin
J Clin Endocrinol Metab. 2006 Jan;91(1):54-9
16263827
Ciba Found Symp. 1985;117:266-83
3836818
Science. 1983 Mar 4;219(4588):1089-91
6823571
Chronobiol Int. 2009 May;26(4):709-25
19444751
J Biol Rhythms. 2005 Aug;20(4):353-65
16077154
J Biol Rhythms. 1997 Oct;12(5):457-66
9376644
J Clin Pharmacol. 2000 Jul;40(7):781-4
10883420
J Physiol. 2003 Jun 15;549(Pt 3):945-52
12717008
J Biol Rhythms. 2003 Aug;18(4):318-28
12932084
J Biol Rhythms. 2002 Apr;17(2):181-93
12002165
Am J Physiol. 1997 Apr;272(4 Pt 2):R1178-88
9140018
Int J Chronobiol. 1976;4(2):97-110
1027738
Sleep Med. 2009 Mar;10(3):287-94
18805055
J Biol Rhythms. 2006 Oct;21(5):362-72
16998156
Chronobiol Int. 2005;22(6):1093-106
16393710
Chronobiol Int. 1998 Jan;15(1):71-83
9493716
J Biol Rhythms. 1996 Jun;11(2):113-25
8744239
Am J Physiol Regul Integr Comp Physiol. 2002 Feb;282(2):R454-63
11792655
PLoS One. 2008 Aug 26;3(8):e3055
18725972
Sleep. 2005 Jan;28(1):33-44
15700719
J Physiol. 2008 Jan 15;586(2):639-47
18006583
Science. 1989 Jun 16;244(4910):1328-33
2734611
J Pineal Res. 2004 Apr;36(3):192-4
15009510
Brain Res. 1995 Aug 7;688(1-2):77-85
8542325
J Biol Rhythms. 1999 Jun;14(3):227-36
10452335